HC Wainwright Reaffirms Buy Rating for Aquestive Therapeutics (NASDAQ:AQST)

Aquestive Therapeutics (NASDAQ:AQST)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report released on Thursday,Benzinga reports. They presently have a $10.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 320.17% from the company’s previous close.

A number of other research analysts also recently commented on the company. Alliance Global Partners reissued a “buy” rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Raymond James set a $7.00 price objective on shares of Aquestive Therapeutics in a report on Friday, March 7th. Finally, Lake Street Capital cut their target price on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, March 7th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Aquestive Therapeutics presently has an average rating of “Buy” and an average target price of $10.67.

Aquestive Therapeutics Price Performance

Shares of NASDAQ:AQST opened at $2.38 on Thursday. The business has a 50-day moving average of $2.76 and a two-hundred day moving average of $3.37. The firm has a market capitalization of $236.38 million, a PE ratio of -5.29 and a beta of 2.02. Aquestive Therapeutics has a 12 month low of $2.12 and a 12 month high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.07). The company had revenue of $8.72 million for the quarter, compared to analysts’ expectations of $12.23 million. As a group, research analysts anticipate that Aquestive Therapeutics will post -0.46 earnings per share for the current year.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of institutional investors have recently modified their holdings of the business. Summit Wealth & Retirement Planning Inc. bought a new position in Aquestive Therapeutics during the 1st quarter worth $29,000. Victory Capital Management Inc. acquired a new position in shares of Aquestive Therapeutics during the first quarter valued at $31,000. Cambridge Investment Research Advisors Inc. bought a new position in shares of Aquestive Therapeutics during the first quarter worth about $33,000. New York State Common Retirement Fund grew its position in shares of Aquestive Therapeutics by 713.3% during the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock worth $43,000 after acquiring an additional 10,700 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Aquestive Therapeutics in the 4th quarter worth about $44,000. Institutional investors own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.